Breast Cancer Genetics

The Breast: Comprehensive Management of Benign and Malignant Diseases

Volumn , Issue , 2009, Pages 371-415

  Lynch, Henry T ^a,b   Marcus, Joseph N ^c   Lynch, Jane ^b   Snyder, Carrie L ^b   Rubinstein, Wendy S ^d,e  

^a Preventive Medicine and Public Health   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MISSOURI BAPTIST MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85159023900     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5221-0.00021-8     Document Type: Chapter

References (306)

1. A. Jemal, R. Siegel, E. Ward, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57 43-66.
2. C. Eng, L.C. Brody, T.M.U. Wagner, et al. (2001) Interpreting epidemiological research: Blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 38 824-833.
3. D.A. Berry, E.S. Iversen Jr, D.F. Gudbjartsson, et al. (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2 and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20 2701-2712.
4. H. Meijers-Heijboer, A. van den Ouweland, J. Klijn, et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 and BRCA2 mutations. Nat Genet 31 55-59.
5. N.G. Howlett, T. Taniguchi, S. Olson, et al. (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297 606-609.
6. P.D.P. Pharoah, A.C. Antoniou, D.F. Easton and B.A.J. Ponder (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358 2796-2803.
7. P.D. Pharoah, A. Antoniou, M. Bobrow, et al. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31 33-36.
8. M.P. Madigan, R.G. Ziegler, J. Benichou, et al. (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87 1681-1685.
9. M.R. Stratton and N. Rahman (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40 17-22.
10. S.A. Narod, D. Goldgar, L. Cannon-Albright, et al. (1995) Risk modifiers in carriers of BRCA1 mutations. Int J Cancer (Pred Oncol) 64 394-398.
11. H. Jernstrom, C. Lerman, P. Ghadirian, et al. (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354 1846-1850.
12. J-S. Brunet, P. Ghadirian, T.R. Rebbeck, et al. (1998) Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 90 761-766.
13. P.P. Broca (1866) Traité des tumeurs Paris: Asselin
14. H.T. Lynch, A.J. Krush, H.M. Lemon, et al. (1972) Tumor variation in families with breast cancer. JAMA 222 1631-1635.
15. H.T. Lynch and A.J. Krush (1971) Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 133 644-648.
16. J.M. Hall, M.K. Lee, B. Newman, et al. (1990) Linkage of early-onset breast cancer to chromosome 17q21. Science 250 1684-1689.
17. S.A. Narod, J. Feunteun, H.T. Lynch, et al. (1991) Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 388 82-83.
18. Y. Miki, J. Swensen, D. Shattuck-Eidens, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 66-71.
19. R. Wooster, S.L. Neuhausen, J. Mangion, et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 2088-2090.
20. R. Wooster, G. Bignell, J. Lancaster, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378 789-792.
21. H.T. Lynch, K.L. Follett, P.M. Lynch, et al. (1979) Family history in an oncology clinic: Implications for cancer genetics. JAMA 242 1268-1272.
22. K.L. David and P. Steiner-Grossman (1991) The potential use of tumor registry data in the recognition and prevention of hereditary and familial cancer. NY State J Med 91 150-152.
23. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358 1389-1399.
24. W.S. Rubinstein and S.M. O'Neill (2004) Quantitative risk assessment. Advanced therapy of breast disease New York: BC Decker
25. D. Saslow, C. Boetes, W. Burke, et al. (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 75-89.
26. H.T. Lynch, J. Lynch, T. Conway, et al. (1994) Hereditary breast cancer and family cancer syndromes. World J Surg 18 21-31.
27. H.T. Lynch, P. Watson, T.A. Conway, et al. (1993) DNA screening for breast/ovarian cancer susceptibility based on linked markers: A family study. Arch Intern Med 153 1979-1987.
28. N.D. Kauff, L. Scheuer, M.E. Robson, et al. (2001) Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 3 422-425.
29. H.T. Lynch, S.J. Lemon, C. Durham, et al. (1997) A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79 2219-2228.
30. J. Peters (1994) Familial cancer risk–Part I: Impact on today's oncology practice. J Oncol Manage 3 18-30.
31. J. Peters (1994) Familial cancer risk–Part II. Breast cancer risk counseling and genetic susceptiblity testing. J Oncol Manage 3 14-22.
32. E.A. Peterson, K.J. Milliron, K.E. Lewis, et al. (2002) Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11 79-87.
33. L.C. Hartmann, T.A. Sellers, D.J. Schaid, et al. (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 1633-1637.
34. T.R. Rebbeck, A.M. Levin, A. Eisen, et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 1475-1479.
35. S.A. Narod, J-S. Brunet, P. Ghadirian, et al. (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356 1876-1881.
36. A. Eisen, T.R. Rebbeck, W.C. Wood and B.L. Weber (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18 1980-1995.
37. H.T. Lynch, J.F. Lynch and W.S. Rubinstein (2001) Prophylactic mastectomy: Obstacles and benefits. J Natl Cancer Inst 93 1586-1587.
38. L. Scheuer, N. Kauff, M. Robson, et al. (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 1260-1268.
39. N. Andrieu, D.F. Easton, J. Chang-Claude, et al. (2006) Effect of chest x-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the BRCA1/2 Carrier Cohort Study: A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 24 3361-3366.
40. S.A. Narod, J. Lubinski, P. Ghadirian, et al. (2006) Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet Oncol 7 402-406.
41. T.R. Rebbeck, H.T. Lynch, S.L. Neuhausen, et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 1616-1622.
42. H.G. Dyck, T.C. Hamilton, A.K. Godwin, et al. (1996) Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer (Pred Oncol) 69 429-436.
43. M.L. Hensley, M. Castiel and M.E. Robson (2001) Screening for ovarian cancer: What we know, what we need to know. Oncology 14 1601-1607.
44. E.F. Petricoin III, A.M. Ardekani, B.A. Hitt, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 572-577.
45. D.F. Easton, D. Ford and D.T. Bishop (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56 265-271. and the The Breast Cancer Linkage Consortium
46. D. Ford and D.F. Easton (1995) The genetics of breast and ovarian cancer. Br J Cancer 72 805-812.
47. D.F. Easton, D.T. Bishop, D. Ford, et al. (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52 678-701.
48. T.S. Frank, A.M. Deffenbaugh, J.E. Reid, et al. (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20 1480-1490.
49. S. Chen and G. Parmigiani (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 1329-1333.
50. D. Ford, D.F. Easton, D.T. Bishop, et al. (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343 692-695.
51. O. Serova, M. Montagna, D. Torchard, et al. (1996) A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 58 42-51.
52. D. Shattuck-Eidens, M. McClure, J. Simard, et al. (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: Implications for presymptomatic testing and screening. JAMA 273 535-541.
53. B. Bressac-de-Paillerets, Z.C. Di Rocco, S. Gad, et al. (2001) Comparative analysis of methods for detecting BRCA1 rearrangements in breast-ovarian cancer families. Am J Hum Genet 69(suppl 4), 248. [Abstract 377]
54. S.A. Gayther, W. Warren, S. Mazoyer, et al. (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11 428-433.
55. L.H. Saal, S.K. Gruvberger-Saal, C. Persson, et al. (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40 102-107.
56. A.C. Antoniou, O.M. Sinilnikova, J. Simard, et al. (2007) RAD51 135G → C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies. Am J Hum Genet 81 1186-1200.
57. S.N. Stacey, P. Sulem, O.T. Johannsson, et al. (2006) The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med 3 e217.
58. G. Parmigiani, D.A. Berry and O. Aguilar (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 145-158.
59. G. Parmigiani, D.A. Berry, E. Iversen, et al. (1999) Modeling risk of breast cancer and decisions about genetic testing. C. Gatsonis, R.E. Kass, B. Carlin, et al., (Eds) Case studies in Bayesian statistics IV New York: Springer 173-268.
60. G. Parmigiani, S. Chen, E.S. Iversen Jr, et al. (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147 441-450.
61. D.M. Euhus, K.C. Smith, L. Robinson, et al. (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94 844-851.
62. J.N. Weitzel, V.I. Lagos, C.A. Cullinane, et al. (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297 2587-2595.
63. R. Nanda, L.P. Schumm, S. Cummings, et al. (2005) Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294 1925-1933.
64. K.J. Vogel, D.P. Atchley, J. Erlichman, et al. (2007) BRCA1 and BRCA2 genetic testing in Hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25 4635-4641.
65. A.C. Antoniou, R. Hardy, L. Walker, et al. (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45 425-431.
66. J.P. Struewing, L.C. Brody, M.R. Erdos, et al. (1995) Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57 1-7.
67. B.B. Roa, A.A. Boyd, K. Volcik and C.S. Richards (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 185-187.
68. K. Offit, T. Gilewski, P. McGuire, et al. (1996) Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 347 1642-1645.
69. B. Modan, E. Gak, R.B. Sade-Bruchim, et al. (1996) High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. JAMA 276 1823-1825.
70. S.P. Helmrich, S. Shapiro, L. Rosenberg, et al. (1983) Risk factors for breast cancer. Am J Epidemiol 117 35-45.
71. M.C. King, J.H. Marks and J.B. Mandell (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 643-646. and the New York Breast Cancer Study Group
72. C. Oddoux, J.P. Struewing, C.M. Clayton, et al. (1996) The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14 188-190.
73. S.A. Gayther, J. Mangion, P. Russell, et al. (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15 103-105.
74. H.A. Risch, J.R. McLaughlin, D.E.C. Cole, et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 700-710.
75. A. Mitra, C. Fisher, C.S. Foster, et al. (2008) Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98 502-507.
76. H.T. Lynch, P. Watson, T. Conway, et al. (1988) Breast cancer family history as a risk factor for early onset breast cancer. Breast Cancer Res Treat 11 263-267.
77. E.B. Claus, N. Risch and W.D. Thompson (1990) Age of onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131 961-972.
78. C. Mettlin, I. Croghan, N. Natarajan and W. Lane (1990) The association of age and familial risk in a case-control study of breast cancer. Am J Epidemiol 131 973-983.
79. M.M.A. Tilanus-Linthorst, I-M. Obdeijn, W.C.J. Hop, et al. (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials. Clin Cancer Res 13 7357-7362.
80. H. Eerola, P. Vahteristo, L. Sarantaus, et al. (2001) Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. Int J Cancer 93 368-372.
81. W.D. Foulkes, P.O. Chappuis, N. Wong, et al. (2000) Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11 307-313.
82. D. Stoppa-Lyonnet, Y. Ansquer, H. Dreyfus, et al. (2000) Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol 18 4053-4059.
83. G. Rennert, S. Bisland-Naggan, O. Barnett-Griness, et al. (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357 115-123.
84. J. Marcus, P. Watson, L. Linder-Stephenson, et al. (1994) The pathobiology of BRCA1-linked and -unlinked hereditary breast cancer (HBC). Modern Pathol 7 18A. [Abstract]
85. H.T. Lynch, J.N. Marcus, P. Watson and J. Lynch (1991) Familial breast cancer, cancer family syndromes, and predisposition to breast neoplasms. K. Bland, E.M. Copeland (Eds) The breast Philadelphia: WB Saunders 262-291.
86. E.B. Claus, N. Risch, W.D. Thompson, et al. (1990) Relationship between breast histopathology and family history of breast cancer. Am J Epidemiol 131 961-972.
87. J. Marcus, D. Page, P. Watson, et al. (1988) High mitotic grade in hereditary breast cancer. Lab Investig 56 61A. [Abstract]
88. G.M. Mulcahy and R. Platt (1981) Pathologic aspects of familial carcinoma of the breast. H.T. Lynch (Eds) Genetics and breast cancer New York: Van Nostrand Reinhold 65-97.
89. P.P. Rosen, M.L. Lesser, M.A. Senie and D.W. Kinne (1982) Epidemiology of breast carcinoma III: Relationship of family history to tumor type. Cancer 50 171-179.
90. L.S. Erdreich, N.R. Asal and A.F. Hoge (1980) Morphologic types of breast cancer: Age, bilaterality, and family history. South Med J 73 28-32.
91. V.A. LiVolsi, J.L. Kelsey, D.B. Fischer, et al. (1982) Effect of age at first childbirth on risk of developing specific histologic subtype of breast cancer. Cancer 49 1937-1940.
92. H. Stalsberg, D.B. Thomas and E.A. Noonan (1989) The WHO collaborative study of neoplasia and steroid contraceptives. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Cancer 44 399-409.
93. M.D. Lagios, M.R. Rose and F.R. Margolin (1980) Tubular carcinoma of the breast: Association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol 73 25-30.
94. S. Mosimann, J.K.H. Torhorst, W. Weber and H. Muller (1990) Histopathological aspects of familial breast cancer. W. Weber, U.T. Laffer, M. Durig (Eds) Hereditary cancer and preventive surgery Karger: Basel 1-7.
95. E.B. Claus, N. Risch, W.D. Thompson and D. Carter (1993) Relationship between breast histopathology and family history of breast cancer. Cancer 71 147-153.
96. O.K. Glebov, K.E. McKenzie, C.A. White and S. Sukumar (1994) Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 54 3703-3709.
97. J.N. Marcus, D.L. Page, P. Watson, et al. (1997) BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer 80(suppl), 543-556.
98. J.N. Marcus, P. Watson, D.L. Page and H.T. Lynch (1994) The pathology and heredity of breast cancer in younger women. J Natl Cancer Inst Monogr 16 23-34.
99. J.N. Marcus, P. Watson, D.L. Page, et al. (1996) Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77 697-709.
100. J.N. Marcus, P. Watson, D.L. Page, et al. (1997) BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44 275-277.
101. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 1505-1510.
102. F. Eisinger, D. Stoppa-Lyonnet, M. Longy, et al. (1996) Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56 471-474.
103. S.R. Lakhani, J. Jacquemier, J.P. Sloane, et al. (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 1138-1145.
104. B.J. Lynch, J.A. Holden, S.S. Buys, et al. (1998) Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 29 1140-1144.
105. J. Lubinski, B. Gorski, T. Huzarski, et al. (2006) BRCA1-positive breast cancers in young women from Poland. Cancer Res Treat 99 71-76.
106. H. Sobol, D. Stoppa-Lyonnet, B. Bressac-de-Paillerets, et al. (1996) Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 56 3216-3219.
107. O.T. Jóhannsson, I. Idvall, C. Anderson, et al. (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33 362-371.
108. N. Rahman and M.R. Stratton (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32 95-121.
109. J.E. Armes, A.J.M. Egan, M.C. Southey, et al. (1998) The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study. Cancer 83 2335-2345.
110. F. Eisinger, J. Jacquemier, C. Charpin, et al. (1998) Mutations at BRCA1: The medullary breast carcinoma revisited. Cancer Res 58 1588-1592.
111. H. Eerola, P. Heikkilä, A. Tamminen, et al. (2005) Histopathological features of breast tumors in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7 R93-R100.
112. C.T.M. Brekelmans, M.M.A. Tilanus-Linthorst, C. Seynaeve, et al. (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43 867-876.
113. S.R. Lakhani, B.A. Gusterson, J. Jacquemier, et al. (2000) The pathology of familial breast cancer: Histologic features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6 782-789.
114. E. Honrado, A. Osorio, J. Palacios and J. Benitez (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25 5837-5845.
115. J. Marcus, L. Linder-Stephenson, T. Conway, et al. (1993) High S phase fraction in hereditary breast carcinoma. Cytometry 14(suppl 6), 34.
116. J.E. Armes, L. Trute, D. White, et al. (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study. Cancer Res 59 2011-2017.
117. S.R. Lakhani, M.J. van de Vijver, J. Jacquermier, et al. (2002) The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 2310-2318.
118. S. Noguchi, T. Kasugai, Y. Miki, et al. (1999) Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85 2200-2205.
119. M. Colombo, M. Giarola, L. Mariani, et al. (2008) Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. Mod Pathol 21 1262-1270.
120. A.D. Thor, D.H. Moore II, S.M. Edgerton, et al. (1992) Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84 845-855.
121. J.S. Meyer and W. He (1994) High proliferative rates demonstrated by bromodeoxyuridine labeling index in breast carcinomas with p53 overexpression. J Surg Oncol 156 146-152.
122. M. Greenblatt, P. Chappuis, J. Bond, et al. (2001) TP53 Mutations in breast cancer associated with BRCA1 and BRCA2 germline mutations: Distinctive spectrum and structural distribution. Cancer Res 61 4092-4097.
123. I. Hedenfalk, D. Duggan, Y. Chen, et al. (2001) Gene expression profiles in hereditary breast cancer. N Engl J Med 344 539-548.
124. L.J. van't Veer, H. Dai, M. van de Vijver, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. J Clin Pathol 59 611-617.
125. T. Sørlie, R. Tibshirani, J. Parker, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 8418-8423.
126. M. Laasko, N. Loman, Å Borg and J. Isola (2005) Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to BRCA1 tumors. Mod Pathol 18 1321-1328.
127. S. Liu, C. Ginestier, E. Charafe-Jauffret, et al. (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 105 1680-1685.
128. J. Jacquemier, L. Padovani, L. Rabayrol, et al. (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207 260-268.
129. S.M. Rodriguez-Pinilla, Y. Rodriguez-Gil, G. Moreno-Bueno, et al. (2007) Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: An immunohistochemical and gene amplification study. Am J Surg Pathol 31 501-508.
130. C. Bewtra, P. Watson, T. Conway, et al. (1992) Hereditary ovarian cancer: A clinicopathological study. Int J Gynecol Pathol 11 180-187.
131. L.H. Hartwell and M.B. Kastan (1994) Cell cycle control and cancer. Science 266 1821-1928.
132. S.E. Shackney, C.A. Smith, B.W. Miller, et al. (1989) Model for the genetic evolution of solid tumors. Cancer Res 49 3344-3354.
133. C.J. Cornelisse, N. Kuipers-Dijkhoorn, M. van Vliet, et al. (1992) Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer 50 544-548.
134. B. Dutrillaux, M. Gerbault-Seureau, Y. Remvikos, et al. (1991) Breast cancer genetic evolution: I. Data from cytogenetics and DNA content. Breast Cancer Res Treat 19 245-255.
135. Y. Remvikos, M. Gerbault-Seureau, H. Magdelénat, et al. (1992) Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. Breast Cancer Res Treat 23 43-49.
136. L. Melchor, E. Honrado, M.J. Garcia, et al. (2008) Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27 3165-3175.
137. J.S. Meyer (1977) Cellular proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine: Effects of menstrual phase, age, and oral contraceptive hormones. Human Pathol 8 67-81.
138. J. Russo, G. Calaf, L. Roi and I.H. Russo (1987) Influence of age and gland topography on cell kinetics of normal human breast tissue. J Natl Cancer Inst 78 413-418.
139. H. Olsson, J. Ranstam, B. Baldetorp, et al. (1991) Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer 67 1285-1290.
140. J.T. Holt, M.E. Thompson, C.I. Szabo, et al. (1996) Growth retardation and tumour inhibition by BRCA1. Nat Genet 12 298-302.
141. E.M. Jarvis, J.A. Kirk and C.L. Clarke (1998) Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 101 109-115.
142. M.E. Thompson, R.A. Jensen, P.S. Obermiler, et al. (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9 444-450.
143. B.A. Agnarsson, J.G. Jonasson, I.B. Björnsdottir, et al. (1998) Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 47 121-127.
144. A.L. Bane, J.C. Beck, I. Bleiweiss, et al. (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31 121-128.
145. E.M. John, J.L. Hopper and J.C. Beck (2004) The Breast Cancer Family Registry: An infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6 R375-R389.
146. M. Robson, P. Rajan, P.P. Rosen, et al. (1998) BRCA-associated breast cancer: Absence of a characteristic immunophenotype? Cancer Res 58 1839-1842.
147. J. Lubinski, C.M. Phelan, P. Ghadirian, et al. (2004) Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 3 1-10.
148. S.E. Karp, P.N. Tonin, L.R. Begin, et al. (1997) Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80 435-441.
149. N. Loman, O. Johannsson, P-O. Bendahl, et al. (1998) Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 310-319.
150. L.C. Verhoog, C.T.M. Brekelmans, C. Seynaeve, et al. (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351 316-321.
151. D. Ford, D.F. Easton, M. Stratton, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62 676-689.
152. K.E. Malone, J.R. Daling, D.R. Doody, et al. (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66 8297-8308.
153. J. Palacios, E. Honrado, A. Osorio, et al. (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: Differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9 3606-3614.
154. E. Honrado, A. Osorio, R.L. Milne, et al. (2007) Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Modern Pathol 20 1298-1306.
155. G. Keller, H. Vogelsang, I. Becker, et al. (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 155 337-342.
156. P.D.P. Pharoah, P. Guilford and C. Caldas (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121 1348-1353. and the International Gastric Cancer Linkage Consortium
157. P. Kaurah, A. MacMillan, N. Boyd, et al. (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297 2360-2372.
158. H.T. Lynch, P. Kaurah, D. Wirtzfeld, et al. (2008) Hereditary diffuse gastric cancer: Diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 112 2655-2663.
159. T. Huzarski, C. Cybulski, W. Domagala, et al. (2005) Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Res Treat 90 187-189.
160. R.L. Balleine, R. Murali, A.M. Bilious, et al. (2006) Histopathologic features of breast cancer in carriers of ATM gene variants. Histopathology 49 523-532.
161. N.D. Kauff, E. Brogi, L. Scheuer, et al. (2003) Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97 1601-1608.
162. K.L. Smith, M. Adank, N. Kauff, et al. (2007) BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 13 4306-4310.
163. C.C. Sun, G. Lenoir, H. Lynch and S.A. Narod (1996) In-situ breast cancer and BRCA1. Lancet 348 408.
164. J. Jacquemier, F. Eisinger, J-M. Guinebretiere, et al. (1996) Intraductal component and BRCA1-associated breast cancer. Lancet 350 1098.
165. E.B. Claus, S. Petruzella, E. Matloff and D. Carter (2005) Prevalence of BRCA1 and BRCA1 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293 964-969.
166. L.J. Hamilton, A.J. Evans, A.R. Wilson, et al. (2004) Breast imaging findings in women with BRCA1- and BRCA1-associated breast carcinoma. Clin Radiol 59 895-902.
167. V. Bonadona, S. Dussart-Moser, N. Voirin, et al. (2007) Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 101 233-245.
168. E. Warner, D.B. Plewes, K.A. Hill, et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 1317-1325.
169. B. Górski, S.A. Narod and J. Lubinski (2005) A common missense variant in BRCA2 predisposes to early onset breast cancer. Breast Cancer Res 7 1023-1027.
170. P. Watson, J.N. Marcus and H.T. Lynch (1998) Prognosis of BRCA1 hereditary breast cancer. Lancet 351 304-305.
171. W.D. Foulkes, J. Goffin, J.S. Brunet, et al. (2002) Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst 94 1504-1506.
172. D.K. Gaffney, R.M. Brohet, J.A. Holden, et al. (1998) Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47 129-136.
173. U. Hamann and H-P. Sinn (2000) Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 59 185-192.
174. O.T. Jóhannsson, J. Ranstam, Å Borg and H. Olsson (1998) Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16 397-404.
175. D.E. Porter, B.B. Cohen, M.R. Wallace, et al. (1994) Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 81 1512-1515.
176. W.D. Foulkes, N. Wong, J-S. Brunet, et al. (1997) Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3 2465-2469.
177. P. Møller, A. Borg, D.G. Evans, et al. (2002) Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101 555-559.
178. K-A. Phillips, I.L. Andrulis and P.J. Goodwin (1999) Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? J Clin Oncol 17 3653-3663.
179. R.L. Ridolfi, P.P. Rosen, A. Port, et al. (1977) Medullary carcinoma of the breast: A clinicopathologic study with 10 year follow-up. Cancer 40 1365-1385.
180. F. Bertucci, P. Finetti, N. Cervera, et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66 4633-4636.
181. L.C. Verhoog, E.M. Berns, C.T. Brekelmans, et al. (2000) Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18 119s-124s.
182. P.A. James, R. Doherty, M. Harris, et al. (2006) Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. J Clin Oncol 24 707-715.
183. G. Farshid, R.L. Balleine, M. Cummings and P. Waring (2006) Morphology of breast cancer as means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol 30 1357-1366.
184. P. van der Groep, A. Bouter, R. van der Zanden, et al. (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59 611-617.
185. D.W. Abbott, M.L. Freeman and J.T. Holt (1998) Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90 978-985.
186. P.J. Biggs and A. Bradley (1998) A step toward genotype-based therapeutic regimens for breast cancer in patients with BRCA2 mutations? J Natl Cancer Inst 90 951-953.
187. A. Broeks, J.H. Urbanus, A.N. Floore, et al. (2000) ATM-heterozygous germline mutations contribute to breast cancer susceptibility. Hum Genet 66 494-500.
188. C.N. Coleman (1999) Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. Acta Oncologica 38(suppl), 55-59.
189. F. Connor, D. Bertwistle, P.J. Mee, et al. (1997) Tumorigenesis and a DNA repair defect in mice with a truncating BRCA2 mutation. Nat Genet 17 423-430.
190. B. Friedenson (2000) Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer. Medscape General Medicine 2 http://www.medscape.com/viewarticle/408048 Accessed 4 September 2008 Medscape Portals, Inc. Available at
191. D.P. Harkin (2000) Uncovering functionally relevant signaling pathways using microarray-based expression profiling. Oncologist 5 501-507.
192. L.J. Pierce, M. Strawderman, S.A. Narod, et al. (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18 3360-3369.
193. R. Scully, J. Chen, A. Plug, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88 265-275.
194. S.K. Sharan, M. Morimatsu, U. Albrecht, et al. (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 386 804-810.
195. M. Swift, D. Morrell, R.B. Massey and C.L. Chase (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325 1831-1836.
196. B. Turner, E. Harrold, E. Matloff, et al. (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17 3017-3024.
197. A.R. Venkitaraman (1999) Breast cancer genes and DNA repair. Science 286 1100-1102.
198. E. Levy-Lahad, A. Lahad, S. Eisenberg, et al. (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98 3232-3236.
199. A. Bradbury and O.I. Olopade (2006) The case for individualized screening recommendations for breast cancer. J Clin Oncol 24 3328-3330.
200. S. Shanley, K. McReynolds, A. Ardern-Jones, et al. (2006) Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 12 7025-7032.
201. Y.C. Tai, S. Domchek, G. Parmigiani and S. Chen (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99 1811-1814.
202. E.M. Rosen, S. Fan and I.D. Goldberg (2001) BRCA1 and prostate cancer. Cancer Invest 19 396-412.
203. B.S. Carter, T.H. Beaty, G.D. Steinberg, et al. (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89 3367-3371.
204. E.U. Thiessen (1974) Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 34 1102-1107.
205. A.S. Whittemore, A.H. Wu, L.N. Kolonel, et al. (1995) Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 141 732-740.
206. D.T. Bishop and L.A. Kiemeney (1997) Family studies and the evidence for genetic susceptibility to prostate cancer. Semin Cancer Biol 8 45-51.
207. D.E. Anderson and M.D. Badzioch (2001) Familial breast cancer risks: Effects of prostate and other cancers. Cancer 72 114-119.
208. M.F. Jishi, J.H. Itnyre, I.A. Oakley-Girvan, et al. (1995) Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer 76 1416-1421.
209. T.A. Sellers, J.D. Potter, S.S. Rich, et al. (1994) Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 86 1860-1865.
210. H. Tulinius, V. Egilsson, G.H. Olafsdottir, et al. (1992) Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Br Med J 305 855.
211. J.P. Struewing, P. Hartge, S. Wacholder, et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 1401-1408.
212. A.R. Brothman, M.R. Steele, B.J. Williams, et al. (1995) Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Genes Chromosomes Cancer 13 278-284.
213. X. Gao, A. Zacharek, D.J. Grignon, et al. (1995) Localization of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer. Oncogene 11 1241-1247.
214. X. Gao, A. Zacharek, A. Salkowski, et al. (1995) Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 55 1002-1005.
215. Y.S. Murakami, A.R. Brothman, R.J. Leach, et al. (1995) Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosome region 17q. Cancer Res 55 3389-3394.
216. B.J. Williams, E. Jones, X.L. Zhu, et al. (1996) Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 155 720-725.
217. A. Arason, R.B. Barkardóttir and V. Egilsson (1993) Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 52 711-717.
218. A. Gonzalez-Neira, J.M. Rosa-Rosa, A. Osorio, et al. (2007) Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. BMC Genomics 8 299.
219. M. Weischer, S.E. Bojesen, C. Ellervik, et al. (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26 542-548.
220. K. Offit and J.E. Garber (2008) Time to check CHEK2 in families with breast cancer? J Clin Oncol 26 519-520.
221. H.T. Lynch, G.M. Mulcahy, R.E. Harris, et al. (1978) Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 41 2055-2064.
222. F.P. Li and J.F. Fraumeni (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med 71 747-752.
223. F.P. Li and J.F. Fraumeni (1975) Familial breast cancer, soft-tissue sarcomas, and other neoplasms. Ann Intern Med 83 833-834.
224. F.P. Li and J.F. Fraumeni (1982) Prospective study of a family cancer syndrome. JAMA 247 2692-2694.
225. D. Malkin, F.P. Li, L.C. Stron, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250 1233-1238.
226. H.T. Lynch, R.D. McComb, N.K. Osborn, et al. (2000) Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. Cancer 88 433-439.
227. M.H. Brownstein, M. Wolf and J.B. Bikowski (1978) Cowden's disease: A cutaneous marker of breast cancer. Cancer 41 2393-2398.
228. D. Liaw, D.J. Marsh, J. Li, et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 64-67.
229. M.R. Nelen, W.C. van Stavernen, E.A. Peeters, et al. (1997) Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6 1383-1387.
230. C. Eng (1997) Cowden syndrome. J Genet Counsel 6 181-192.
231. D.J. Marsh, P.L.M. Dahia, S. Caron, et al. (1998) Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35 881-885.
232. W. Williard, P. Borgen, R. Bol, et al. (1992) Cowden's disease: A case report with analyses at the molecular level. Cancer 69 2969-2974.
233. B.J. Walton, W.B. Morain, R.D. Baughman, et al. (1986) A further indication for prophylactic mastectomy. Surgery 99 82-86.
234. C.A. Schrager, D. Schneider, A.C. Gruener, et al. (1998) Clinical and pathological features of breast disease in Cowden's syndrome: An underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 29 47-53.
235. E.D. Lynch, E.A. Ostermeyer, M.K. Lee, et al. (1997) Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. Am J Hum Genet 61 1254-1260.
236. R.A. Gatti, I. Berkel, E. Boder, et al. (1988) Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 366 577-580.
237. K. Savitsky, A. Bar-Shira, S. Gilad, et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 1749-1753.
238. M. Swift (1990) Genetic aspects of ataxia-telangiectasia. Immunodefic Rev 2 67-81.
239. D. Morrell, E. Cromartic and M. Swift (1986) Mortality and cancer incidence in 263 patients with ataxia- telangiectasia. J Natl Cancer Inst 77 89-92.
240. D. Morrell, C.L. Chase and M. Swift (1990) Cancers in 44 families with ataxia-telangiectasia. Cancer Genet Cytogenet 50 119-123.
241. M. Swift, C.L. Chase and D. Morrell (1990) Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46 21-27.
242. M. Buyse, C.T. Hartman and M.G. Wilson (1976) Gonadoblastoma and dysgerminoma with ataxia-telangiectasia. Birth Defects 12 165-169.
243. T. Narita and K. Takagi (1984) Ataxia-telangiectasia with dysgerminomas of the right ovary, papillary carcinoma of the thyroid and adenocarcinoma of the pancreas. Cancer 54 1113-1116.
244. M. Swift, D. Morrell, E. Cromartie, et al. (1986) The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39 573-583.
245. M.F. Lavin, K.K. Khanna, H. Beamish, et al. (1994) Defect in radiation signal transduction in ataxia-telangiectasia. Int J Radiat Biol 66(suppl 6), S151-S156.
246. H.T. Lynch, W. Grady, G. Suriano and D. Huntsman (2005) Gastric cancer: New genetic developments. J Surg Oncol 90 114-133.
247. G. Suriano, C. Oliveira, P. Ferreira, et al. (2003) Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 12 575-582.
248. G. Suriano, S. Yew, P. Ferreira, et al. (2005) Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management. Clin Cancer Res 11 5401-5409.
249. C. Oliveira, R. Seruca and C. Caldas (2003) Genetic screening for hereditary diffuse gastric cancer. Expert Rev Mol Diagn 3 201-215.
250. T.R. Rebbeck, Y. Wang, P.W. Kantoff, et al. (2001) Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61 5420-5424.
251. T.R. Rebbeck, P.A. Kantoff, K. Krithivas, et al. (1999) Modification of BRCA1-associated breast cancer penetrance by androgen receptor CAG repeat length variants. Am J Hum Genet 64 1371-1377.
252. C.J. Fabian, B.F. Kimler, C.M. Zalles, et al. (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92 1217-1227.
253. J.A. O'Shaughnessy, B-M. Ljung, W.C. Dooley, et al. (2002) Ductal lavage and the clinical management of women at high risk for breast carcinoma: A commentary. Cancer 94 292-298.
254. W.C. Dooley, B-M. Ljung, U. Veronesi, et al. (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93 1624-1632.
255. C.M. Perou, T. Sorlie, M.B. Eisen, et al. (2000) Molecular portraits of human breast tumours. Nature 406 747-752.
256. T. Sørlie, C.M. Perou, R. Tibshirani, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 10869-10874.
257. L.J. van 't Veer, H. Dai, M.J. van de Vijver, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536.
258. S. Gruvberger, M. Ringner, Y. Chen, et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61 5979-5984.
259. K.J. Martin, E. Graner, Y. Li, et al. (2001) High sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci USA 98 2646-2651.
260. K. Kudoh, M. Ramanna, R. Ravatn, et al. (2000) Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60 4161-4166.
261. S.A. Narod, P. Sun, P. Ghadirian, et al. (2001) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A casecontrol study. Lancet 357 1467-1470.
262. S.A. Narod, H. Risch, R. Moslehi, et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339 424-428.
263. P.A. Marchbanks, J.A. McDonald, H.G. Wilson, et al. (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346 2025-2032.
264. H.T. Lynch (1967) Hereditary factors in carcinoma. H.T. Lynch (Eds) Recent results in cancer research vol 12 New York: Springer-Verlag
265. H.T. Lynch (1969) Dynamic genetics counseling for clinicians Springfield, IL: CC Thomas
266. H.T. Lynch, H.A. Guirgis, F. Brodkey, et al. (1976) Early age of onset in familial breast cancer: Genetic and cancer control implications. Arch Surg 111 126-131.
267. H.T. Lynch and A.J. Krush (1971) Genetic predictability in breast cancer risk: Surgical implications. Arch Surg 103 84-88.
268. H.T. Lynch, P.M. Lynch, W.A. Albano, et al. (1979) Hereditary cancer: Ascertainment and management. CA Cancer J Clin 29 216-232.
269. R.E. Harris, H.T. Lynch and H.A. Guirgis (1978) Familial breast cancer: Risk to the contralateral breast. J Natl Cancer Inst 60 955-960.
270. L.C. Hartmann, D.J. Schaid, J.E. Woods, et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 77-84.
271. H. Meijers-Heijboer, B. van Geel, W.L.J. van Putten, et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 159-164.
272. L.C. Verhoog, C.T.M. Brekelmans, C. Seynaeve, et al. (1999) Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17 3396-3402.
273. K.A. Metcalfe, J. Lubinski, P. Ghadirian, et al. (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26 1093-1097.
274. T.M. Tuttle, E.B. Habermann, E.H. Grund, et al. (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 25 5203-5209.
275. N.D. Kauff, J.M. Satagopan, M.E. Robson, et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 1609-1615.
276. N.D. Kauff, S.M. Domchek, T.M. Friebel, et al. (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26 1331-1337.
277. B. Meiser, P. Butow, A. Barratt, et al. (1999) Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75 122-129.
278. C. Lerman, C. Hughes, R.T. Croyle, et al. (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31 75-80.
279. S. van Dijk, M.S. van Roosmalen, W. Otten and P.F.M. Stalmeier (2008) Decision making regarding prophylactic mastectomy: Stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol 26 2358-2363.
280. N. Hallowell, I. Jacobs, M. Richards, et al. (2001) Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy. J Med Genet 38 683-691.
281. W. Droegemueller (1994) Screening for ovarian cancer: Hopeful and wishful thinking. Am J Obstet Gynecol 170 1095-1098.
282. National Institutes of Health Consensus Development Conference Statement (1994) Ovarian cancer: Screening, treatment, and follow-up. Gynecol Oncol 55 S4-S14.
283. D. Deapen, L. Liu, C. Perkins, et al. (2002) Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer 99 747-750.
284. K.M. Kash, J.C. Holland, M.S. Halper and D.G. Miller (1992) Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 84 24-30.
285. C. Lerman, M. Daly, C. Sands, et al. (1993) Mammography adherence and psychological distress among women at risk for breast cancer. J Natl Cancer Inst 85 1074-1080.
286. C. Lerman and M. Schwartz (1993) Adherence and psychological adjustment among women at high risk for breast cancer. Breast Cancer Res Treat 28 145-155.
287. H.B. Valdimarsdottir, D.H. Bovbjerg, K.M. Kash, et al. (1995) Psychological distress in women with a familial risk of breast cancer. Psycho-Oncology 4 133-141.
288. C. Lerman, K. Kash and M. Stefanek (1994) Younger women at increased risk for breast cancer: Perceived risk, psychological well-being, and surveillance behavior. J Natl Cancer Inst Monogr 16 171-176.
289. M. Schwartz, C. Lerman, M. Daly, et al. (1995) Utilization of ovarian cancer screening by women at increased risk. Cancer Epidemiol Biomarkers Prev 4 269-273.
290. C. Lerman, B.K. Rimer, M. Daly, et al. (1994) Recruiting high risk women into a breast cancer health promotion trial. Cancer Epidemiol Biomarkers Prev 3 271-276.
291. C. Lerman, E. Lustbader, B. Rimer, et al. (1995) Effects of individualized breast cancer risk counseling: A randomized trial. J Natl Cancer Inst 87 286-292.
292. H. Chaliki, S. Loader, J.C. Levenkron, et al. (1995) Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 85 1133-1135.
293. M. Bloch, M. Fahy, S. Fox and M.R. Hayden (1989) Predictive testing for Huntington disease II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet 32 217-224.
294. D. Craufurd, A. Dodge, L. Kerzin-Storrar and R. Harris (1989) Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 2 603-605.
295. K.L. Hudson, M.K. Holohan and F.S. Collins (2008) Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 358 2661-2663.
296. H.T. Lynch, M.J. Severin, M.J. Mooney and J.F. Lynch (1995) Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome. Gynecol Oncol 57 23-26.
297. A. Katskee (1994) Katskee v. Blue Cross/Blue Shield of Nebraska Nebraska Supreme Court No. S-92–1002
298. v. Beggs (1984) Pacific Mutual Life Insurance Company 171 Ga.App. 204, 218 S.E.2d 836
299. v. Cheney (1989) Bell National Life 315 Md. 761, 556 A.2d 1135
300. v. Silverstein (1930) Metropolitan Life Insurance Company 171 N.E. 914
301. W. Burke, L.E. Pinsky and N.A. Press (2001) Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet (Semin Med Genet) 106 233-240.
302. H.T. Lynch, C.R. Boland, M.A. Rodriguez-Bigas, et al. (2007) Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 25 3534-3542.
303. U.S. Department of Health and Human Services (2005) HIPAA—General information http://www.cms.hhs.gov/HIPAAGenInfo/ Accessed 29 January 2007 Available at
304. H.T. Lynch (2001) Family Information Service and hereditary cancer. Cancer 91 625-628.
305. A. Eisen and B.L. Weber (2001) Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations—facts and controversy. N Engl J Med 345 207-208.
306. V.R. Grann, J.S. Jacobson, D. Thomason, et al. (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis. J Clin Oncol 20 2520-2529.